Patent ID: 8318448

Claim:
A method of serodiagnosis of early stage invasive candidiasis in a patient comprising: performing a serological assay in a serum sample of the patient for the detection of IgG2 antibody to a phosphopeptidomannan fraction of the cell wall of Candida albicans , and IgG1 antibody to native a Candida albicans cell wall antigen, and beta (1-3) glucan using the serum sample of the patient, wherein: (a) the simultaneous detection of the serum IgG2 antibody to the phosphopeptidomannan fraction of the cell wall of Candida albicans , and the serum IgG1 antibody to the native Candida albicans cell wall antigen with a significantly increased antibody level for the IgG1 antibody to the native Candida albicans cell wall antigen and the IgG2 antibody to the phosphopeptidomannan fraction of the cell wall antigen of the Candida albicans , compared to titers of serum antibodies of healthy human controls to said antigens, and (b) the simultaneous detection of the beta (1-3) glucan in the serum sample indicate the serodiagnosis of the early stage invasive candidiasis in the patient.